North America Leads January Biotech Funding Round with Nearly $2 Billion Raised, Oncology and Obesity Startups Dominate 1 year ago ByJohnIn Breaking NewsInvestmentsPartnershipsVenture Capital
Survey Reveals Clinicians Feel Ill-Prepared for Sex Differences in Disease Despite Frequent Observations 1 year ago ByJohnIn Industry ConferencesInvestmentsPeopleTop Stories
ALX Oncology Reveals Durable CD47 Blocker Responses in HER2-Positive Gastric Cancer at ASCO-GI 1 year ago ByJohnIn Pharma Industry UpdatesStartupsTop Stories
Oncolytics Biotech To Reveal New Pelareorep Efficacy and Safety Data at ASCO-GI for Anal and Pancreatic Cancers 1 year ago ByJohnIn BreakthroughsClinical TrialsTop Stories
Dogwood Therapeutics Begins Phase IIb Dosing of Halneuron® for Chemotherapy-Induced Neuropathic Pain 1 year ago ByJohnIn BreakthroughsClinical Trials
Nature Highlights Self-Driving Labs and Advanced Immunotherapies Among Top Technologies to Watch in 2025 1 year ago ByJohnIn BreakthroughsClinical TrialsTechnology
GSK’s Jemperli Receives EMA Approval for First-Line Endometrial Cancer Treatment 1 year ago ByJohnIn Clinical TrialsFeatured AnalysisLeadersPharma Industry Updates
FDA Accepts Arrowhead’s New Drug Application for Plozasiran in Treating Familial Chylomicronemia Syndrome 1 year ago ByJohnIn Biopharma HighlightsFDA Approvals
FDA Approves Datopotamab Deruxtecan (Datroway) for HR-Positive, HER2-Negative Breast Cancer 1 year ago ByJohnIn FDA ApprovalsInnovationLeadersResearch Updates
Evaxion Completes Dosing in Phase II Trial of Personalized Cancer Vaccine EVX-01, Paving the Way for AI-Driven Oncology 1 year ago ByJohnIn AI & DataBreakthroughsClinical Trials
Avance Clinical Captures Australia’s Early-Phase CRO Market, While Idorsia Prepares Strategic Pivot at JPM Week 1 year ago ByJohnIn Biopharma HighlightsResearch UpdatesStartups
FDA Grants Rare Pediatric Designation to ViGeneron’s RP Gene Therapy VG901; EMA Pushes for EU Clinical Trials Transition 1 year ago ByJohnIn BreakthroughsClinical TrialsResearch Updates
Denali, Agios, Cabaletta and Walden Drive Rare Disease and Immuno-Innovations into the Spotlight at JP Morgan Week 1 year ago ByJohnIn Breaking NewsBreakthroughsIndustry ConferencesLeadersPeopleTop Stories
Mereo BioPharma Advances Rare Disease Programs with Setrusumab and Alvelestat Milestones 1 year ago ByJohnIn Biopharma HighlightsBreakthroughsTop Stories
Bio-Path Holdings Gears Up for Dual Progression of Oncology and Obesity Programs in 2025 1 year ago ByJohnIn Industry ConferencesPeopleResearch Updates
